The Scripps Research Institute

Covx Technologies Ireland Limited

Covx Technology Ireland, Ltd.

Sirius Therapeutics, Inc.

Tollnine, Inc.

Pfizer Healthcare Ireland

Curt William Bradshaw

Dingguo Liu

Venkata Ramana Doppalapudi

Abhijit Suresh Bhat

Sukumar Sakamuri

Laxman Eltepu

Jing-Yu Lai

Chi-Huey Wong

Bin Liu

Gang Chen

Yanwen Fu

Joel Desharnais

Son Lam

Bryan R Meade

Bryan Douglas Oates

Gwo-Jenn Shen

David Tumelty

John M Rizzo

Ayman Kabakibi

Alice Lee

Olivier Alexandre Laurent

Richard Ryan Preston

Wei Hong Yu

Giuseppe Dello Iacono

Edward Hyungsuk Ha

Joseph Stock

Jing Yu Lai

Lauren Diane Wood

Disclosed are P-stereogenic groups that may be used in the synthesis of compounds including stereochemically enriched P-stereogenic phosphorothioates. P-stereogenic groups may be provided in nucleoside phosphoramidites including a sugar bonded to a nucleobase and to a stereochemically enriched phosphoramidite as well as methods of their use and methods of making them.

Chiral phosphoramidite auxiliaries and methods of their use

Disclosed are polynucleotide constructs having a strand linked to a moiety carrying one or more auxiliary moieties. Also disclosed are polynucleotide constructs interrupted with a sugar analogue, and polynucleotide constructs with stereochemical{circumflex over ( )} enriched phosphorothioates. The polynucleotide constructs may be provided as hybridized polynucleotide constructs. Also featured are methods of delivery a polynucleotide construct to a cell and methods of reducing the expression of a protein in a cell by contacting the cell with the disclosed polynucleotide construct or hybridized polynucleotide construct.

Polynucleotide constructs

Disclosed are chiral phosphoramidite auxiliary compositions for diastereoselective synthesis of stereochemically enriched oligonucleotides, and nucleoside phosphoramidite compounds comprising the same. Exemplary structures of the chiral phosphoramidite auxiliary compositions include Formulas (IA) and (IB). 

Immunomodulating polynucleotides are disclosed. The immunomodulating polynucleotides may contain 5-modified uridine, 5-modified cytidine, a total of from 6 to 16 nucleotides, and/or one or more abasic spacers and/or internucleoside phosphotriesters. Also disclosed are conjugates containing a targeting moiety and one or more immunomodulating polynucleotides. The immunomodulating polynucleotides and conjugates may further contain one or more auxiliary moieties. Also disclosed are compositions containing the immunomodulating polynucleotides or the conjugates containing one or more stereochemically enriched internucleoside phosphorothioates. Further disclosed are pharmaceutical compositions containing the immunomodulating polynucleotides or the conjugates and methods of their use.

Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use

The present invention provides various uses of VEGF binding peptides, including methods to treat disorders associated with abnormal angiogenesis. In addition, the invention provides VEGF peptides conjugated to antibodies alone and in conjunction with other anti-angiogenic molecules.

Anti-angiogenic compounds

The present invention provides methods of treating (including preventing) a disease or condition associated with abnormal angiogenesis in a subject include administering a therapeutically effective amount of an AA targeting compound of the invention to the subject. The AA targeting compounds comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody.

Methods of treating a disease or condition associated with abnormal angiogenesis

The present invention relates to Multifunctional Antibody Conjugates, comprising an antibody or antigen binding portion thereof, comprising at least a fragment of a light chain constant kappa region (CL&#x3ba;) comprising Kaccording to Kabat numbering; a linker comprising the formula X-Y-Z, wherein Z is a group is covalently connected to the antibody through the side chain of K, Y is a linear or branched biologically compatible connecting chain, and X is a group covalently connected to at least one Effector Moiety. The invention further provides specific MAC compounds and compositions of the invention.

Multifunctional antibody conjugates

The present invention provides VEGF binding peptides. In addition, the invention provides VEGF peptides conjugated to antibodies alone and in conjunction with other anti-angiogenic molecules. Various uses of the peptides and compounds are provided, including methods to treat disorders associated with abnormal angiogenesis.

The present invention provides AA targeting compounds which comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to treat disorders connected to abnormal angiogenesis.

The present invention provides a substantially pure culture of Pseudomonas sp. strain PED having the ATCC designation 49794. Processes for making R-configured alcohols and for transferring a hydride ion from an R-configured alcohol to the pro-R face of NAD using PED alcohol dehydrogenase isolated and purified from Pseudomonas sp. strain PED are also provided.

Pseudomonas sp. ATCC No. 49794 alcohol dehydrogenase

The present invention discloses the preparation of R-configured trialkylsilylethynyl .alpha.-alcohols from similarly substituted .alpha.-ketones, and vice versa, catalyzed by the alcohol dehydrogenase of Lactobacillus kefir, ATCC No. 35411. Also disclosed is the acceptance or transfer of a hydride ion from or to the pro-R face of NADPH or NADP, respectively, as catalyzed by that enzyme.

Growing community of inventors

San Diego, CA, United States of America

Curt William Bradshaw